FI4401833T3 - Gpr52:n muuntajayhdisteitä - Google Patents
Gpr52:n muuntajayhdisteitäInfo
- Publication number
- FI4401833T3 FI4401833T3 FIEP22778038.4T FI22778038T FI4401833T3 FI 4401833 T3 FI4401833 T3 FI 4401833T3 FI 22778038 T FI22778038 T FI 22778038T FI 4401833 T3 FI4401833 T3 FI 4401833T3
- Authority
- FI
- Finland
- Prior art keywords
- disorder
- disorders
- salt
- compound
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2113186.7A GB202113186D0 (en) | 2021-09-15 | 2021-09-15 | GPR52 Modulator compounds |
| PCT/GB2022/052328 WO2023041909A1 (en) | 2021-09-15 | 2022-09-15 | Gpr52 modulator compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4401833T3 true FI4401833T3 (fi) | 2025-11-25 |
Family
ID=78149263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP22778038.4T FI4401833T3 (fi) | 2021-09-15 | 2022-09-15 | Gpr52:n muuntajayhdisteitä |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20240376070A1 (enExample) |
| EP (1) | EP4401833B1 (enExample) |
| JP (1) | JP2024535860A (enExample) |
| KR (1) | KR20240058852A (enExample) |
| CN (1) | CN117999258A (enExample) |
| AU (1) | AU2022348201A1 (enExample) |
| CA (1) | CA3232606A1 (enExample) |
| CL (1) | CL2024000742A1 (enExample) |
| DK (1) | DK4401833T3 (enExample) |
| ES (1) | ES3053759T3 (enExample) |
| FI (1) | FI4401833T3 (enExample) |
| GB (1) | GB202113186D0 (enExample) |
| HR (1) | HRP20251420T1 (enExample) |
| IL (1) | IL311015A (enExample) |
| LT (1) | LT4401833T (enExample) |
| MX (1) | MX2024003248A (enExample) |
| PL (1) | PL4401833T3 (enExample) |
| PT (1) | PT4401833T (enExample) |
| RS (1) | RS67399B1 (enExample) |
| SI (1) | SI4401833T1 (enExample) |
| SM (1) | SMT202500449T1 (enExample) |
| WO (1) | WO2023041909A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4139284A1 (en) | 2020-04-22 | 2023-03-01 | Neurocrine Biosciences, Inc. | Gpr52 modulators and methods of use |
| WO2025252061A1 (zh) * | 2024-06-04 | 2025-12-11 | 海思科医药集团股份有限公司 | 一种gpr52激动剂及其在医药上的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2009107391A1 (ja) * | 2008-02-27 | 2011-06-30 | 武田薬品工業株式会社 | ６員芳香環含有化合物 |
| MX373876B (es) | 2015-04-29 | 2020-03-26 | Arena Pharm Inc | 1-heteroaril-indolin-4-carboxamidas como moduladores de gpr52 útiles para el tratamiento o prevención de trastornos relacionados a las mismas. |
| CN111094278B (zh) * | 2017-09-13 | 2023-07-14 | 诺华股份有限公司 | 二苯基衍生物及其用途 |
| CN114650992A (zh) * | 2019-11-08 | 2022-06-21 | 赫普泰雅治疗有限公司 | Gpr52调节剂化合物 |
| GB202003668D0 (en) | 2020-03-13 | 2020-04-29 | Heptares Therapeutics Ltd | GPR52 Modulator compounds |
-
2021
- 2021-09-15 GB GBGB2113186.7A patent/GB202113186D0/en not_active Ceased
-
2022
- 2022-09-15 KR KR1020247006746A patent/KR20240058852A/ko active Pending
- 2022-09-15 PL PL22778038.4T patent/PL4401833T3/pl unknown
- 2022-09-15 DK DK22778038.4T patent/DK4401833T3/da active
- 2022-09-15 SI SI202230201T patent/SI4401833T1/sl unknown
- 2022-09-15 US US18/689,590 patent/US20240376070A1/en active Pending
- 2022-09-15 AU AU2022348201A patent/AU2022348201A1/en active Pending
- 2022-09-15 SM SM20250449T patent/SMT202500449T1/it unknown
- 2022-09-15 HR HRP20251420TT patent/HRP20251420T1/hr unknown
- 2022-09-15 IL IL311015A patent/IL311015A/en unknown
- 2022-09-15 ES ES22778038T patent/ES3053759T3/es active Active
- 2022-09-15 CA CA3232606A patent/CA3232606A1/en active Pending
- 2022-09-15 PT PT227780384T patent/PT4401833T/pt unknown
- 2022-09-15 JP JP2024516935A patent/JP2024535860A/ja active Pending
- 2022-09-15 WO PCT/GB2022/052328 patent/WO2023041909A1/en not_active Ceased
- 2022-09-15 EP EP22778038.4A patent/EP4401833B1/en active Active
- 2022-09-15 RS RS20251139A patent/RS67399B1/sr unknown
- 2022-09-15 LT LTEPPCT/GB2022/052328T patent/LT4401833T/lt unknown
- 2022-09-15 CN CN202280062419.2A patent/CN117999258A/zh active Pending
- 2022-09-15 MX MX2024003248A patent/MX2024003248A/es unknown
- 2022-09-15 FI FIEP22778038.4T patent/FI4401833T3/fi active
-
2024
- 2024-03-13 CL CL2024000742A patent/CL2024000742A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023041909A1 (en) | 2023-03-23 |
| IL311015A (en) | 2024-04-01 |
| SMT202500449T1 (it) | 2026-01-12 |
| CL2024000742A1 (es) | 2024-09-27 |
| US20240376070A1 (en) | 2024-11-14 |
| JP2024535860A (ja) | 2024-10-02 |
| PL4401833T3 (pl) | 2026-02-16 |
| LT4401833T (lt) | 2025-12-10 |
| MX2024003248A (es) | 2024-04-02 |
| DK4401833T3 (da) | 2025-11-17 |
| RS67399B1 (sr) | 2025-11-28 |
| ES3053759T3 (en) | 2026-01-26 |
| KR20240058852A (ko) | 2024-05-07 |
| HRP20251420T1 (hr) | 2026-01-02 |
| AU2022348201A1 (en) | 2024-03-28 |
| EP4401833B1 (en) | 2025-10-22 |
| EP4401833A1 (en) | 2024-07-24 |
| GB202113186D0 (en) | 2021-10-27 |
| PT4401833T (pt) | 2025-11-14 |
| SI4401833T1 (sl) | 2026-01-30 |
| CA3232606A1 (en) | 2023-03-23 |
| CN117999258A (zh) | 2024-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Brandel et al. | Structural aspects of solid solutions of enantiomers | |
| JP2007262401A (ja) | 活性エネルギー線硬化性光学的立体造形用樹脂組成物およびそれを硬化した光造形物 | |
| HRP20251420T1 (hr) | Gpr52 modulatorski spojevi | |
| Sun et al. | Direct access to β-seleno sulfones at room temperature through selenosulfonylation of alkenes | |
| Jameson et al. | Application of crystallization-induced asymmetric transformation to a general, scalable method for the resolution of 2, 8-disubstituted Tröger’s base derivatives | |
| CN104370791B (zh) | 一种左乙拉西坦的纯化方法 | |
| SE458118B (sv) | Foerfarande foer framstaellning av ett injicerbart kondroitinpolysulfat, en produkt som kan erhaallas genom detta foerfarande och en farmaceutisk komposition | |
| JP2013147506A (ja) | イオン性液体の精製方法 | |
| Castagnolo et al. | Enantioselective carbolithiation of S-alkenyl-N-aryl thiocarbamates: kinetic and thermodynamic control | |
| JP2024535860A5 (enExample) | ||
| JPWO2018123301A1 (ja) | 四フッ化硫黄の製造方法 | |
| Van Leusen et al. | Synthesis of (+)-(neomenthylsulfonyl) methyl isocyanide. Synthesis and absolute configuration of (R)-(+)-2-methylcyclobutanone and (S)-(-)-2-methylcyclobutanone | |
| CN102942593B (zh) | 一种光引发剂双(2,4,6-三甲基苯甲酰基)苯基氧化膦的合成方法 | |
| CN102558006A (zh) | 一种分离维生素d3和速甾醇t3的方法 | |
| Pavia et al. | Benzo-fused bicyclic imides | |
| RU2024109992A (ru) | Соединения-модуляторы gpr52 | |
| Basavaiah et al. | A study toward understanding the role of a phosphorus stereogenic center in (5S)-1, 3-diaza-2-phospha-2-oxo-3-phenylbicyclo (3.3. 0) octane derivatives as catalysts in the borane-mediated asymmetric reduction of prochiral ketones | |
| TWI546312B (zh) | 以無溶劑製程製備環磷醯胺之方法 | |
| Van der Werf et al. | An NMR Study of intramolecular shielding in Alkyl N (Arylsulfonyl) Methyl]‐Carbamates,‐Thiolcarbamates,‐Thionocarbamates, and‐Dithiocarbamates | |
| CN104098529B (zh) | 无机金属硫化物促进二硫化碳与邻卤苯胺反应合成2-巯基苯并噻唑的方法 | |
| CN108424409A (zh) | 一种固体酸催化合成光引发剂2,4-二乙基硫杂蒽酮的方法 | |
| CN110105318B (zh) | 一种α-吡喃酮类化合物的绿色合成方法 | |
| Coles et al. | The liberation, characterisation and X-ray crystal structure of 1, 5, 9-triphospha-1, 5, 9-tris (2-propyl) cyclodecane | |
| Aggarwal et al. | Synthesis, X-ray crystal structure, equilibration studies and anion chemistry of trans-1, 3-dithiane 1, 3-dioxide | |
| TW200745134A (en) | One pot synthesis of tetrazole derivatives of sirolimus |